Anzeige
Meldung des Tages: ALLZEITHOCH: EchoIQ bei 1$ AUD – der größte Trigger steht unmittelbar bevor

Savara News

Aktie
WKN:  A2DQ2B ISIN:  US8051111016 US-Symbol:  SVRA Branche:  Biotechnologie Land:  USA
5,88 $
-0,21 $
-3,45%
4,9782 € 15.04.26
Depot/Watchlist
Marktkapitalisierung *
1,11 Mrd. €
Streubesitz
11,72%
KGV
-6,40
Index-Zuordnung
-

Savara News

15.04.26 - Businesswire
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the FDA has extended the ...
14.04.26 - Businesswire
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster ...
07.04.26 - Businesswire
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the MHRA has accepted the ...
30.03.26 - Businesswire
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the EMA has validated the ...
13.03.26 - Businesswire
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and ...
06.03.26 - Businesswire
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (the “Company”) (Nasdaq: SVRA ), a clinical-​stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has received the Day 74 ...
04.03.26 - Businesswire
Savara Announces Participation in 2026 Citizens Life Sciences Conference
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management ...
20.02.26 - Businesswire
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-​stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the BLA for ...
13.02.26 - Businesswire
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
04.02.26 - Businesswire
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management ...
27.01.26 - Businesswire
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and ...
07.11.25 - PR Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders PR Newswire
07.11.25 - PR Newswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara PR Newswire
07.11.25 - PR Newswire
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA PR Newswire
07.11.25 - PR Newswire
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
06.11.25 - PR Newswire
Shareholders of Savara Inc. Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights - SVRA
Shareholders of Savara Inc. Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights - SVRA PR Newswire
04.11.25 - PR Newswire
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
04.11.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA PR Newswire
03.11.25 - PR Newswire
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA PR Newswire
03.11.25 - PR Newswire
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire

Newssuche

Videos

newspaper
07.04.26 +1,32%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »